放化疗后复发食管癌再程治疗的研究进展  

Progress of re-treatment of recurrent esophageal cancer after chemoradiotherapy

作　　者：孙曼 李晓敏[2] Sun Man;Li Xiaomin(Graduate School,Shanxi Medical University,Taiyuan 030001,China;The Second Ward of Thoracic Radiotherapy,Shanxi Province Cancer Hospital,Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences,Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,China)

机构地区：[1]山西医科大学研究生院,太原030001 [2]山西省肿瘤医院、中国医学科学院肿瘤医院山西医院、山西医科大学附属肿瘤医院胸部放疗二病区,太原030013

出　　处：《肿瘤研究与临床》2023年第4期313-316,共4页Cancer Research and Clinic

摘　　要：食管癌是消化系统中最常见的恶性肿瘤。由于临床症状隐匿,疾病发现时大多已到局部晚期,对失去手术机会的患者推荐同步放化疗,然而放化疗后复发率高。复发患者的临床治疗采用联合化疗、放疗及手术治疗,但复发患者治疗后生存率仍不理想。近年来免疫治疗在各项实体肿瘤中应用,对晚期及复发转移性食管癌的疗效及安全性也得到了认可。文章通过对放化疗后复发食管癌患者包括免疫治疗在内各项治疗的相关文献进行总结,旨在为该类患者提供疗效高毒性低的治疗手段。Esophageal cancer is the most common malignant tumor in the digestive system in China.Because of the hidden clinical symptoms,the disease has reached the local advanced stage once discovered.For patients who have lost the opportunity of surgery,synchronous chemoradiotherapy is recommended,however,the recurrence rate after chemoradiotherapy is still high.Chemotherapy,radiotherapy and surgery are commonly used for recurrent patients,but the survival rate of recurrent patients after treatment is not satisfying.In recent years,immunotherapy has been successfully applied in various solid tumors,and its efficacy and safety in the treatment of advanced and recurrent metastatic esophageal cancer have also been recognized in the field of esophageal cancer.This article aims to provide high efficacy and low toxicity treatment methods for patients with recurrent esophageal cancer after chemoradiotherapy through summarizing the relevant literatures of various treatments including immunotherapy.

关 键 词：食管肿瘤 同步放化疗 免疫疗法 复发 

分 类 号：R735.1[医药卫生—肿瘤]